Literature DB >> 19832713

Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose.

J Gonçalves-Pereira1, A Martins, P Póvoa.   

Abstract

Gentamicin is extensively used in the treatment of severe Gram-negative bacterial infections. A loading dose of 7 mg/kg is recommended to achieve a maximum concentration (C(max)) above 16 mg/L. We studied gentamicin pharmacokinetic data from patients treated between January 2006 and June 2008 in two intensive-care units. The Sawchuk and Zaske one-compartment pharmacokinetic model was used to estimate the gentamicin volume of distribution (the 32 patients had a median age of 68 years (23 men)). The median volume of distibution (V(d)) per kilogram of body weight (V(d)/kg) was 0.41 L/kg (interquartile range of 0.36-0.46 L/kg), with no correlations with age, Charlson comorbidity score, sequential organ failure assessment (SOFA) score and creatinine serum level (r(2) = 0.016, 0.058, 0.037, and 0.067, respectively). Women had a significantly higher median V(d)/kg (0.50 vs. 0.40 L/kg, p 0.002) and lower C(max) (15.2 vs. 18.5 mg/L, p 0.016), despite similar dose/kg. In a logistic regression model, only sex (female: OR 0.032; 95% CI 0.03-0.387) and dose/kg (per mg/kg: OR 3.21; 95% CI 1.17-8.79) were significantly associated with the achievement of C(max) above 16 mg/L. Gentamicin clearance was 57 mL/min (interquartile range of 44.7-78 mL/min) and decreased with age (r(2) = 0.178, p 0.016), SOFA score (r(2) = 0.199, p 0.011) and creatinine clearance (r(2) = 0.258, p 0.003). Gentamicin V(d) was increased in critically ill patients, particularly in women. Therefore, high gentamicin loading doses should be given to all patients, especially women, independently of organ failure. Gentamicin clearance decreases with age, SOFA score, and renal failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19832713     DOI: 10.1111/j.1469-0691.2009.03074.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  What is new in the use of aminoglycosides in critically ill patients?

Authors:  Dimitrios K Matthaiou; Jan De Waele; George Dimopoulos
Journal:  Intensive Care Med       Date:  2014-07-04       Impact factor: 17.440

2.  Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF).

Authors:  Deirdre M D'Arcy; Owen I Corrigan; Evelyn Deasy; Caitríona M Gowing; Maria B Donnelly
Journal:  Eur J Clin Pharmacol       Date:  2014-11-26       Impact factor: 2.953

3.  Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.

Authors:  J Robert; Y Péan; S Alfandari; J-P Bru; J-P Bedos; C Rabaud; R Gauzit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-09       Impact factor: 3.267

4.  Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Authors:  Valerio Del Bono; Daniele Roberto Giacobbe; Anna Marchese; Andrea Parisini; Carmen Fucile; Erika Coppo; Valeria Marini; Antonio Arena; Alexandre Molin; Antonietta Martelli; Angelo Gratarola; Claudio Viscoli; Paolo Pelosi; Francesca Mattioli
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

5.  Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.

Authors:  Sha He; Zeneng Cheng; Feifan Xie
Journal:  Drug Des Devel Ther       Date:  2022-01-06       Impact factor: 4.162

6.  Antibiotics and extracorporeal circulation--one size does not fit all.

Authors:  João Gonçalves-Pereira; Bruno Oliveira
Journal:  Crit Care       Date:  2014-12-19       Impact factor: 9.097

7.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

8.  An international survey on aminoglycoside practices in critically ill patients: the AMINO III study.

Authors:  Claire Roger; Benjamin Louart; Loubna Elotmani; Greg Barton; Leslie Escobar; Despoina Koulenti; Jeffrey Lipman; Marc Leone; Laurent Muller; Caroline Boutin; Julien Amour; Iouri Banakh; Joel Cousson; Jeremy Bourenne; Jean-Michel Constantin; Jacques Albanese; Jason A Roberts; Jean-Yves Lefrant
Journal:  Ann Intensive Care       Date:  2021-03-19       Impact factor: 6.925

9.  Improving peak concentrations of a single dose regime of gentamicin in patients with sepsis in the emergency department.

Authors:  Maarten Cobussen; Patricia M Stassen; Dirk Posthouwer; Frank H van Tiel; Paul H M Savelkoul; Thomas Havenith; Michiel B Haeseker
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

10.  Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function.

Authors:  Cornelis Smit; Anne M van Schip; Eric P A van Dongen; Roger J M Brüggemann; Matthijs L Becker; Catherijne A J Knibbe
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.